Why It Matters

A Senate Judiciary Committee hearing titled "Hearings To Examine Prescribing Sunshine, Focusing On How Competition And Transparency Lowers Prescription Drug Costs" is scheduled for Tuesday, August 4. The session comes as pharmacy benefit manager (PBM) reforms in the Consolidated Appropriations Act take effect. It also follows a Senate discussion draft for 340B reform that proposes tighter oversight of contract pharmacies, expanded hospital reporting, and provisions directing more prescription drug savings to eligible patients.

The Big Picture

The Consolidated Appropriations Act, 2026, included "delinking" provisions separating PBM compensation from Medicare Part D list prices and rebates, a change the Congressional Budget Office estimated will reduce federal spending by $444 million over 10 years. In May, the Trump administration announced an expansion of TrumpRx.gov to feature more than 600 generic medications.

Separately, a Senate discussion draft on 340B reform proposes tighter oversight of contract pharmacies, additional reporting requirements for hospitals, and provisions directing more prescription drug savings to eligible patients. Stakeholders may comment on the draft through Friday, August 28.

Sen. Dick Durbin (D-IL) serves as Ranking Member of the Judiciary Committee. Industry observers anticipate that PBM practices and insurer consolidation will dominate the hearing's discussion.

Lobbying records show sustained engagement from multiple stakeholders on the issue. Patients for Affordable Drugs Now Inc. reported $30,000 in lobbying activity in quarter one of 2026 focused on prescription drug competition and pricing. GoodRx Inc. filed a similar disclosure for the same period, reporting $60,000 in activity on ways to lower prescription drug costs. Elevance Health Inc. lobbied on health insurance price transparency and Medicare-related issues during the quarter.

The Bottom Line

The hearing lands at a moment when Congress, the administration, and industry are pursuing parallel tracks on drug pricing, from PBM delinking already in law to a 340B draft still open for comment. Testimony from the Judiciary Committee could shape how lawmakers reconcile competing proposals once the August recess ends.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article